FDA Grants Fast Track to SAB-142 for New-Onset Type 1 Diabetes
SABS sits 33% above its 52-week low of $2.1.
Summary
SAB Biotherapeutics received FDA Fast Track designation for SAB-142, its disease-modifying immunotherapy for new-onset Stage 3 type 1 diabetes. The designation recognizes the program's potential to address an unmet medical need and enables more frequent FDA interactions and potential priority review. SAB-142 is currently in the registrational Phase 2b SAFEGUARD study with enrollment expected to complete in Q4 2026 and topline data anticipated in 2H 2027. This follows the company's recent $100 million capital raise, which extended its cash runway. The Fast Track designation is a meaningful regulatory milestone that could accelerate the development timeline for a large-market indication.
At the time of this announcement, SABS was trading at $2.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $257.5M. The 52-week trading range was $2.10 to $5.15. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.